

## CURRICULUM VITAE

NAME: CLAUDIA MAURI PhD

PRESENT TITLE Professor of Immunology, UCL.

QUALIFICATIONS:

1996 Ph.D. (equiv.) Università degli Studi di Roma/Imperial College  
1989 Doctor in Biology Università degli Studi di Roma (110/110 cum laude)  
1984 Maturità scientifica Rome

ACADEMIC AND PROFESSIONAL APPOINTMENTS:

2015 –present Vice-Dean International Faculty Medical Science  
2011 - present Professor of Immunology, UCL  
2009 – 2011 Reader  
2005 - 2009 Senior Lecturer, Centre for Rheumatology Research, Department of Medicine,  
University College London  
2003 - 2004 Senior Research Fellow, Centre for Rheumatology Research, Department of  
Medicine, University College London  
1995 - 2003 Post-Doctoral Research, Kennedy Institute of Rheumatology/ Imperial College,  
London  
1992 - 1995 Junior Scientist, Istituto Superiore di Sanità, Microbiology Department. Rome,  
Italy  
1990 - 1992 Junior Scientist, ENEA, Rome, Italy

RECENT PUBLICATIONS: <https://orcid.org/0000-0001-9761-2625>

1: Rosser EC, Piper CJM, Matei DE, Blair PA, Rendeiro AF, Orford M, Alber DG,  
Krausgruber T, Catalan D, Klein N, Manson JJ, Drozdov I, Bock C, Wedderburn LR,  
Eaton S, Mauri C. Microbiota-Derived Metabolites Suppress Arthritis by  
Amplifying Aryl-Hydrocarbon Receptor Activation in Regulatory B Cells. *Cell  
Metab.* 2020 Apr 7;31(4):837-851.e10. doi: 10.1016/j.cmet.2020.03.003. Epub 2020  
Mar 25. PMID: 32213346; PMCID: PMC7156916.

2: Piper CJM, Rosser EC, Oleinika K, Nistala K, Krausgruber T, Rendeiro AF,  
Banos A, Drozdov I, Villa M, Thomson S, Xanthou G, Bock C, Stockinger B, Mauri  
C. Aryl Hydrocarbon Receptor Contributes to the Transcriptional Program of  
IL-10-Producing Regulatory B Cells. *Cell Rep.* 2019 Nov 12;29(7):1878-1892.e7.  
doi: 10.1016/j.celrep.2019.10.018. PMID: 31722204; PMCID: PMC6856759.

3: Wincup C, Menon M, Smith E, Schwartz A, Isenberg D, Jury EC, Mauri C; ABIRISK  
Consortium. Presence of anti-rituximab antibodies predicts infusion-related

reactions in patients with systemic lupus erythematosus. *Ann Rheum Dis.* 2019 Aug;78(8):1140-1142. doi: 10.1136/annrheumdis-2019-215200. Epub 2019 Mar 28. PMID: 30923233; PMCID: PMC6691858.

4: Menon M, Rosser EC, Mauri C. Identification and Isolation of Regulatory B Cells in Mouse and Human. *Methods Mol Biol.* 2019;1899:55-66. doi: 10.1007/978-1-4939-8938-6\_5. PMID: 30649765.

5: Magill L, Adriani M, Berthou V, Chen K, Gleizes A, Hacein-Bey-Abina S, Hincelin-Mery A, Mariette X, Pallardy M, Spindeldreher S, Szely N, Isenberg DA, Manson JJ, Jury EC, Mauri C. Low Percentage of Signal Regulatory Protein  $\alpha/\beta$  Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis Patients. *Front Immunol.* 2018 Dec 5;9:2865. doi: 10.3389/fimmu.2018.02865. PMID: 30568660; PMCID: PMC6290031.

6: Oleinika K, Mauri C, Salama AD. Effector and regulatory B cells in immune-mediated kidney disease. *Nat Rev Nephrol.* 2019 Jan;15(1):11-26. doi: 10.1038/s41581-018-0074-7. PMID: 30443016.

7: Thomas M, Ponce-Aix S, Navarro A, Riera-Knorrenschild J, Schmidt M, Wiegert E, Kapp K, Wittig B, Mauri C, Dómine Gómez M, Kollmeier J, Sadjadian P, Fröhling KP, Huber RM, Wolf M; IMPULSE study team. Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study. *Ann Oncol.* 2018 Oct 1;29(10):2076-2084. doi: 10.1093/annonc/mdy326. PMID: 30137193; PMCID: PMC6225892.

8: Burton AR, Pallett LJ, McCoy LE, Suveizdyte K, Amin OE, Swadling L, Alberts

E, Davidson BR, Kennedy PT, Gill US, Mauri C, Blair PA, Pelletier N, Maini MK.  
Circulating and intrahepatic antiviral B cells are defective in hepatitis B. *J Clin Invest.* 2018 Oct 1;128(10):4588-4603. doi: 10.1172/JCI121960. Epub 2018 Aug 9. PMID: 30091725; PMCID: PMC6159997.

9: Piper CJM, Wilkinson MGL, Deakin CT, Otto GW, Dowle S, Duurland CL, Adams S, Marasco E, Rosser EC, Radziszewska A, Carsetti R, Ioannou Y, Beales PL, Kelberman D, Isenberg DA, Mauri C, Nistala K, Wedderburn LR.  
CD19<sup>+</sup>CD24<sup>hi</sup>CD38<sup>hi</sup> B Cells Are Expanded in Juvenile Dermatomyositis and Exhibit a Pro-Inflammatory Phenotype After Activation Through Toll-Like Receptor 7 and Interferon- $\alpha$ . *Front Immunol.* 2018 Jun 22;9:1372. doi: 10.3389/fimmu.2018.01372. PMID: 29988398; PMCID: PMC6024011.

10: Adriani M, Nytrova P, Mbogning C, Hässler S, Medek K, Jensen PEH, Creeke P, Warnke C, Ingenhoven K, Hemmer B, Sievers C, Lindberg Gasser RL, Fissolo N, Deisenhammer F, Bocskei Z, Mikol V, Fogdell-Hahn A, Kubala Havrdova E, Broët P, Dönnès P, Mauri C, Jury EC; ABIRISK Consortium. Monocyte NOTCH2 expression predicts IFN- $\beta$  immunogenicity in multiple sclerosis patients. *JCI Insight.* 2018 Jun 7;3(11):e99274. doi: 10.1172/jci.insight.99274. PMID: 29875313; PMCID: PMC6124413.

11: Oleinika K, Rosser EC, Matei DE, Nistala K, Bosma A, Drozdov I, Mauri C.  
CD1d-dependent immune suppression mediated by regulatory B cells through modulations of iNKT cells. *Nat Commun.* 2018 Feb 15;9(1):684. doi: 10.1038/s41467-018-02911-y. PMID: 29449556; PMCID: PMC5814456.

12: Mauri C, Menon M. Human regulatory B cells in health and disease: therapeutic potential. *J Clin Invest.* 2017 Mar 1;127(3):772-779. doi: 10.1172/JCI85113. Epub 2017 Mar 1. PMID: 28248202; PMCID: PMC5330739.

- 13: Aravena O, Ferrier A, Menon M, Mauri C, Aguillón JC, Soto L, Catalán D. TIM-1 defines a human regulatory B cell population that is altered in frequency and function in systemic sclerosis patients. *Arthritis Res Ther*. 2017 Jan 19;19(1):8. doi: 10.1186/s13075-016-1213-9. PMID: 28103916; PMCID: PMC5248463.
- 14: Rosser EC, Mauri C. A clinical update on the significance of the gut microbiota in systemic autoimmunity. *J Autoimmun*. 2016 Nov;74:85-93. doi: 10.1016/j.jaut.2016.06.009. Epub 2016 Jul 29. PMID: 27481556.
- 15: Menon M, Blair PA, Isenberg DA, Mauri C. A Regulatory Feedback between Plasmacytoid Dendritic Cells and Regulatory B Cells Is Aberrant in Systemic Lupus Erythematosus. *Immunity*. 2016 Mar 15;44(3):683-697. doi: 10.1016/j.immuni.2016.02.012. Epub 2016 Mar 8. PMID: 26968426; PMCID: PMC4803914.
- 16: Vlkova M, Ticha O, Nechvatalova J, Kalina T, Litzman J, Mauri C, Blair PA. Regulatory B cells in CVID patients fail to suppress multifunctional IFN- $\gamma$ + TNF- $\alpha$ + CD4+ T cells differentiation. *Clin Immunol*. 2015 Oct;160(2):292-300. doi: 10.1016/j.clim.2015.06.013. Epub 2015 Jul 29. PMID: 26232673.
- 17: Mauri C, Menon M. The expanding family of regulatory B cells. *Int Immunol*. 2015 Oct;27(10):479-86. doi: 10.1093/intimm/dxv038. Epub 2015 Jun 12. PMID: 26071023; PMCID: PMC4587489.
- 18: Strom AC, Cross AJ, Cole JE, Blair PA, Leib C, Goddard ME, Rosser EC, Park I, Hultgårdh Nilsson A, Nilsson J, Mauri C, Monaco C. B regulatory cells are increased in hypercholesterolaemic mice and protect from lesion development via IL-10. *Thromb Haemost*. 2015 Oct;114(4):835-47. doi: 10.1160/TH14-12-1084. Epub 2015 Jun 11. PMID: 26063196.

19: Rup B, Pallardy M, Sikkema D, Albert T, Allez M, Broet P, Carini C, Creeke P, Davidson J, De Vries N, Finco D, Fogdell-Hahn A, Havrdova E, Hincelin-Mery A, C Holland M, H Jensen PE, Jury EC, Kirby H, Kramer D, Lacroix-Desmazes S, Legrand J, Maggi E, Maillère B, Mariette X, Mauri C, Mikol V, Mulleman D, Oldenburg J, Paintaud G, R Pedersen C, Ruperto N, Seitz R, Spindeldreher S, Deisenhammer F; ABIRISK Consortium. Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium. *Clin Exp Immunol*. 2015 Sep;181(3):385-400. doi: 10.1111/cei.12652. Epub 2015 Jul 2. PMID: 25959571; PMCID: PMC4557374.